ASH 2023 | MRD-guided treatment cessation in multiple myeloma
Benjamin Derman, MD, University of Chicago, Chicago, IL, shares insights into the use of measurable residual disease (MRD) status to guide treatment decisions in patients with multiple myeloma (MM). He references several clinical trials (MASTER; NCT03224507, MRD2STOP; NCT04108624, NCT02406144) as evidence for making decisions about the discontinuation of treatment based on MRD negativity, whilst emphasizing that this approach may not be effective in patients with high-risk cytogenic abnormalities. Additionally, he mentions the challenge of treating patients who do not attain MRD-negativity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen, COTA Healthcare
Independent reviewer for a clinical trial: BMS
